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Second trimester abortion remains a common procedure world-
wide. Dilatation and evacuation (D&E) is the surgical method of
choice, if the surgical expertise and facilities are available.
Adequate cervical dilatation preoperatively is a prerequisite for
a safe D&E. Medical abortion using misoprostol together with
mifepristone is the medical method of choice. The recommended
regimen is 200 mg mifepristone followed by 800 mg of vaginal
misoprostol 36–48 h later. Subsequent doses of 400 mg of miso-
prostol can be given orally every 3 h up to a maximum of four
more doses. Proper preoperative assessment would not only help
to provide safe abortion treatment, but it also guides the choice of
method. If the expertise and facilities of both methods are avail-
able, both methods should be discussed and offered to the patient
so that the patient can make an informed choice.
 2010 Elsevier Ltd. All rights reserved.C
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Second-trimester abortion refers to the abortion performed between 13 and 28 gestational weeks.
Abortion is one of themost commonprocedures doneworldwidewith an estimated 42million induced
abortions in 2003, compared with 46 million in 1995. The induced abortion rate in 2003 was 29 per
1000 women, of which, 48% of all abortions worldwide were unsafe, and more than 97% of all unsafe
abortions were in developing countries.1 Second-trimester abortions account for 11.2% of all abortions
in the United States (USA) in 2005 and 9.7% in the United Kingdom (UK) in 2008.2,3 In general, two-
thirds of all major complications of abortions are attributable to those performed in the secondx: þ852 28550947.
nghye@hku.hk (E.H.Y. Ng), pcho@hkusub.hku.hk (P.C. Ho).
d. All rights reserved.
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trimester.4 As the complication ratewasmuch higher in abortions performed in the second trimester, it
is important to facilitate the access to first trimester abortion to reduce the incidence of second
trimester abortions, and to provide facilities for safe second trimester abortion in order to reduce the
complication rates. However, the rate of second trimester abortions has remained the same in the
recent decade.2 In this article, the following issues on second trimester abortions are discussed: pre-
abortion assessment and preparation, surgical methods, medical methods, patients with previous
caesarean section and the factors affecting the choice of the method.
Pre-abortion assessment and preparation
To provide safe second trimester abortion, there should be careful pre-abortion assessment and
preparation. A detailed history and careful physical examination should be performed to exclude possible
medical disorders, risk factors for complications of abortion and to assess the gestational age of the
pregnancy. If there is a discrepancy between the gestational age as estimated by the date of the last
menstrualperiodand theuterine size, anultrasoundexamination shouldbeperformed foraccuratedating
of thepregnancy. Thesewill provide important information for thephysicians and thepregnantwomen to
choose the best-available treatment methods.5 Counselling before abortion by appropriately trained
personnel, such as nursing specialists and contraceptive counsellors, is also vital to reduce the risk of
regrets andpsychological burdens, and to plan for future contraception to decrease the chanceof repeated
abortions of unintended pregnancies. Proper assessment remains the most important way to reduce the
chance of complications. Because of the possibilities of serious complications, second trimester abortions
should be performed in facilities with easy access to blood transfusion and emergency laparotomy.
Surgical methods
Surgical abortion in the second trimester is the most common method in some countries such as
USA and UK. Dilatation and evacuation (D&E) is the most common surgical method used for second
trimester abortion. D&E was done in 98.6% of abortions between 13 and 15 weeks, 95.4% between 16
and 20 weeks and 85.1% at 21 weeks or later in USA,2 and 95% of abortions after 13 weeks in UK.3
Before D&E became the surgical method of choice in the 1970s, hysterotomy and hysterectomy,
which are rarely done nowadays, were the only options for abortion after 17 weeks of gestation, other
than medical methods. Hysterotomy, resembling a caesarean delivery on a pre-term uterus, consists of
a laparotomy, incision on the uterus, removal of the product of gestation through the incision, together
with the repair of the uterus. However, a low, transverse uterine incision is usually not possible, thus
committing the patient to caesarean deliveries in future pregnancies.6 This procedure is only per-
formed when there is an obstruction of the cervix, either by uterine anomaly or by fibroid, or when the
myometrium is too thin to safely manipulate instruments or to induce abortion. Hysterectomy should
only be performed when there are other indications for hysterectomy.
D&E refers to transcervical instrumental evacuation of the pregnant uterus at13 weeks’ gestation.
7 The most common method of D&E involves preparation with cervical dilatation, aspiration of
amniotic fluid with disarticulation and removal of the foetus through the prepared cervix using strong,
elongated extraction forceps.
One variant of D&E is known as intact dilatation and extraction (D&X). According to the American
College of Obstetricians and Gynecologists (ACOG) Statement of Policy on abortion, published in 2007,
D&X included four elements: (1) deliberate dilatation of cervix, usually over a sequence of days; (2)
instrumental conversion of the foetus to a footling breech; (3) breech extraction of the body excepting
the head; and (4) partial evacuation of the intracranial contents of a living foetus to effect vaginal
delivery of a dead but otherwise intact foetus.8 There is no good evidence regarding which method is
the better option, while a retrospective analysis revealed the safety of both methods.9
Complications
Complications of D&E include cervical injury, incomplete evacuation, bleeding, infection and
perforation of the uterus. Adequate cervical dilatation before D&E can help reduce the risk ofPlease cite this article in press as: Lee VCY, et al., Issues in second trimester induced abortion (medical/
surgical methods), Best Practice & Research Clinical Obstetrics and Gynaecology (2010), doi:10.1016/
j.bpobgyn.2010.02.008
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complications. It was shown by various studies that the more the Laminaria is used resulting in
a decreased need for intra-operative cervical dilatation, the less likely it is to have complications such
as cervical injury or vaginal bleeding during D&E.10,11
Bleeding is the most common complication of surgical abortion in the second trimester. Its inci-
dence increases with gestational age.7 The use of uterotonics, such as oxytocin, is commonly employed
to reduce the amount of blood loss of the procedures. However, its efficacy was not proved by any
prospective trial. A retrospective analysis over 8 years’ data showed the effectiveness of uterine artery
embolisation as the sole method to control the haemorrhage due to disruption of fibroid, placenta
accreta and cervical lacerations.12 There was also a case report of using tamponade with a large
intrauterine balloon to successfully manage intra-operative haemorrhage during D&E at 18 weeks of
gestation for foetal aneuploidy not resulting from uterine atony.13
Uterine perforation is another serious complication in second trimester surgical abortion, with the
incidence of 0.32%.14 It was shown that the use of routine intra-operative ultrasound guidance during
D&E reduced the rate of perforation.15U
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OCervical dilatation for surgical abortion in the second trimester
To ensure a safe D&E, adequate cervical dilatation is vital, which could be acquired with either
mechanical or pharmaceutical agents.
One commonlyusedmechanical agent is Laminaria, which is a genus of brownalgae. After dehydration
and sterilisation, the stem of the seaweed forms a thin rod. When it is inserted into the cervical canal, it
absorbs moisture and then expands, leading to the dilatation of the cervix. The major drawbacks include
the need for overnight placement for adequate dilatation and the lack of uniformity with unpredictable
dilatation in a natural product.16 Lamicel, a synthetic osmotic dilator, is a sterile tent of dehydrated
polyvinyl alcohol impregnatedwith 450 mgMgSO4, which absorbswater and swells fourfold in diameter
after 4 h, with faster action than Laminaria. However, Skjeldestad et al. reported only about half of the
Lamicel remained in place after overnight insertion, whereas the other half was partially displaced or
completely expelled infirst-trimester abortion.17 Lamicel is effective for cervical ripeningwith insertion of
few hours in surgical abortion of gestations up to 16weeks.18,19When used overnight, Lamicel is effective
up to 17 weeks of gestation.20 Dilapan-S is a hygroscopic cervical dilator that is manufactured from an
aquacryl, a proprietary hydrogel. There are three different sizes available and the manufacturer recom-
mends overnight insertion for second trimester abortion with more than one dilator according to gesta-
tion. It continues to expand over 24 h, although it can achieve 10-mm dilation after 2–4 h of insertion.
There are no published data on the direct comparison between Dilapan and Lamicel.
Prostaglandin (PG) analogues, specifically the PGE1 analogue, misoprostol, are often used as an
alternative or an adjuvant for cervical ripening. Various routes of administration were studied.
Adequate cervical preparation was achieved in 32 women between 14 and 16 weeks of gestation with
600 mg of buccal misoprostol 2–4 h prior to D&E.21 A randomised, double-blinded, controlled trial
comparing 400 mg of vaginal misoprostol, given 3–4 h preoperatively, with overnight Laminaria at
13–16 weeks of gestation showed that significantly faster procedures and greater preoperative dila-
tation were achieved with Laminaria than with misoprostol. More patients in the misoprostol group
required additional manual dilatation.22 Edelman et al. reported a randomised trial of preoperative
cervical preparation with overnight Laminaria and either buccal placebo or 400 mg buccal misoprostol
approximately 90 min before second trimester surgical abortion. It showed misoprostol treatment did
not improve the initial mean dilatation achieved with Laminaria alone in either gestation of 13–
15-week or 16–20-week groups, while a sub-analysis of gestations 19 weeks or more demonstrated
significantly greater dilatation in the misoprostol group. Subjects receiving misoprostol reported
significantly more cramping than those receiving placebo.23
Mifepristone, an antiprogestin, thoughnotwidely available inmany countries, is a potentially effective
cervical ripening agent. Its use together with misoprostol, either orally or sublingually, was proved to be
more effective, in terms of the average cervical dilatation and shorter operative time thanmisoprostol in
either route alone.24 However, mifepristone is expensive and not available in many countries. Therefore,
fromtheavailabledata, thepreoperative insertionof intracervical tents appears tobe themethodof choicePlease cite this article in press as: Lee VCY, et al., Issues in second trimester induced abortion (medical/
surgical methods), Best Practice & Research Clinical Obstetrics and Gynaecology (2010), doi:10.1016/
j.bpobgyn.2010.02.008
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in dilating the cervix before D&E in pregnancies less than 19 weeks. In more advanced pregnancies, the
combined use of intracervical tents and misoprostol may be more appropriate.
Medical abortion
Medical abortions in the second trimester are widely employed worldwide, especially where
surgical expertise is not available. The popular methods three decades ago include the use of intra-
uterine instillation of hypertonic saline, rivanol or hyperosmolar urea. As these methods are invasive
andmay be associated with serious complications such as disseminated intravascular coagulation, they
are seldom used nowadays25 although they are still used in some developing countries, such as
Uzbekistan, as reported by Kapp et al. A randomised trial reported by Kapp et al. showed that when
compared with misoprostol alone, the use of intrauterine hypertonic saline plus a PG F2 analogue was
associated with a significantly longer procedure time and significantly more complications, such as
retained placenta and haemorrhage. Both providers and patients gave a higher procedural satisfaction
score to the misoprostol method and the authors suggested adopting the misoprostol method.26
Oxytocin is frequently used as an induction agent at term gestation and its use in second trimester
abortion has also been studied. A prematurely terminated randomised trial showed a significantly
shorter induction-to-delivery interval and a higher induction success rate in the group using miso-
prostol 600 mg followed by 400 mg every 4 h for five doses, compared with the escalating dose-
concentrated oxytocin infusions plus vaginal misoprostol 400 mg, then 200 mg every 6 h and then
100 mg. 27 Another regimen of 200 mg of mifepristone orally between 36 and 48 h before the vaginal
administration of 800 mg of misoprostol, together with amniorrhexis and intravenous oxytocin infusion
was studied in a descriptive study with 428 women of gestation between 19.1 and 25.6 weeks.
Complete abortion occurred in 90.4%, while 9.6% of patients required D&Ewith a uterine rupture in one
woman with a previous caesarean section noted.28
Medical abortion with PGs
A breakthrough in the field of medical abortion is the development of PGs and their analogues. The
natural PGs were less effective than their analogues and their use was also associated with a higher
incidence of side effects. PGF analogues were also associated with a high incidence of gastrointestinal
side effects and they were often given intra-amniotically to reduce the incidence of side effects. They
are now mostly replaced by the PGE analogues.
Sulprostone, a 16-phenoxy-w-17,18,19,20-tetranor PGE2 methyl sulphonylamide, was used in the
1990s for second trimester abortion. It can be given intramuscularly. It was as effective as carboprost
(15 methyl PGF2a analogue) but the incidence of side effects was less. However, it was withdrawn from
the market due to its association with myocardial infarction caused by coronary spasm.29
The most commonly used PG analogues for second trimester abortion nowadays are the PGE1
analogues, namely misoprostol (15-deoxy-16-hydroxy-16-methyl PGE1) and gemeprost
(16,16,-dimethyl-trans-d2-PGE1methyl ester). Both of themare effective in second trimester abortion. A
numberof randomised trials havebeen conducted to compare these twoanalogues. A systematic review
of six randomised trials on the use of vaginal misoprostol compared with gemeprost revealed similar
efficacy, whereas misoprostol was associatedwith reduced narcotic analgesia requirement and surgical
evacuation of the uterus.30 However, different regimens of misoprostol were used in many of the trials
included in this systematic review. There was evidence that the regimen of vaginal misoprostol 400 mg
every 3 h is, in fact, more effective than the standard gemeprost regimen of 1 mg every 3 h. In a study
comparing 400 mg of vaginal misoprostol every 3 hwith 1 mg of gemeprost every 3 h, the induction-to-
abortion interval was significantly shorter in the vaginal misoprostol group.31 Another randomised trial
comparing the same regimens of misoprostol and gemeprost also showed that women in the miso-
prostol group aborted earlier, while there was more pyrexia in the gemeprost group.32
There are additional advantages to using misoprostol over gemeprost. Misoprostol is cheap and
stable at room temperature, while gemeprost must be stored below –10 C. These properties make
misoprostol particularly attractive in developing countries. Therefore, misoprostol is the PG of choice in
medical abortion. However, in many countries, only gemeprost, but not misoprostol, is registered forPlease cite this article in press as: Lee VCY, et al., Issues in second trimester induced abortion (medical/
surgical methods), Best Practice & Research Clinical Obstetrics and Gynaecology (2010), doi:10.1016/
j.bpobgyn.2010.02.008
V.C.Y. Lee et al. / Best Practice & Research Clinical Obstetrics and Gynaecology xxx (2010) 1–11 5
ARTICLE IN PRESS
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
YBEOG989_proof  27 February 2010  5/11termination of pregnancy. While this should not prevent the off-label use of misoprostol in many
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Regimens of misoprostol
Various regimens of using misoprostol have been studied.33 A randomised trial compared three
regimens of misoprostol: 200 mg misoprostol at 6-h intervals, 400 mg misoprostol at 6-h intervals and
a loading dose of 600 mg misoprostol followed by 200 mg at 6-h intervals. The results showed that
among these three regimens, the preferred regimen for intravaginal misoprostol was 400 mg at
6-hintervals as it was associated with a shorter commencement to abortion interval than the 200 mg
regimen and fewer maternal side-effects than the 600 mg loading dose regimen.34 However, two other
randomised trials showed that the regimen of vaginal misoprostol 400 mg every 6 h is less effective
than vaginal misoprostol every 3 h. Both trials compared the regimen of 400 mg vaginal misoprostol
every 3 h up to a maximum of five doses with the regimen of 400 mg vaginal misoprostol every 6 h up
to a maximum of three doses in 24 h. Both trials showed significantly shorter induction-to-abortion
interval in the 3-hourly regimen, with a higher incidence of fever in one trial.35,36 Therefore, the
3-hourly regimen was probably the most optimal.
Although misoprostol was licensed for oral use, various studies showed that it is also effective when
given by other routes. The intravaginal route of administration was shown to have a shorter induction-
to-abortion interval compared with the oral route in a small prospective study, while the overall success
rates were similar in the two groups.37 Using vaginal administration of misoprostol alone was shown to
have a significantly shorter mean induction-to-delivery interval (19.617.5 h vs. 34.5 28.2 h, P< 0.01)
and shorter length of hospital stay (32.317.3 h vs. 50.9 27.9 h, P< 0.01) when compared with oral
administration. Therewas an increase in febrilemorbidity in the vaginal group (25% vs. 6.7%, P¼ 0.046).38
The vaginal route was also showed to be more effective than the oral route after mifepristone priming.33
Therewas also a reduction in the incidence of side effects. However,morewomenpreferred the oral route.
Because of the preference of women for the oral route, the alternative of sublingual admin-
istration of misoprostol was investigated. A pharmacokinetic study showed that after sublingual
administration, misoprostol was absorbed more rapidly than after vaginal administration and the
peak serum level as well as the area under the time concentration curve of misoprostol acid, the
active metabolite of misoprostol, were significantly higher than those after oral or vaginal
administration. However, the serum levels of misoprostol acid were maintained for a longer period
after vaginal administration than with oral or sublingual administration.39 A subsequent study on
the pharmacokinetics of misoprostol after either vaginal or sublingual administration of repeated
doses of misoprostol every 3 h showed that after vaginal administration, the serum levels of
misoprostol acid were slightly higher in the vaginal group after 3 h, if there was no significant
bleeding. If there was significant bleeding, the serum levels of misoprostol acid declined despite
repeated doses. This is probably due to the impaired absorption of misoprostol when there was
significant bleeding. A prospective randomised trial of 120 women at 12–20 weeks of gestation
comparing sublingual with oral misoprostol (400 mg every 3 h for a maximum of five doses)
36–48 h after 200 mg of mifepristone showed no significant difference in the success rate at 24 h
with 91.4% in the sublingual group and 85.0% in the oral group, but the median induction-to-
abortion interval was significantly shorter (P¼ 0.009) in the sublingual group. The incidence of
fever was higher in the sublingual group. The incidence of other side effects was similar in both
groups.40 A randomised trial comparing the efficacy of vaginal or sublingual misoprostol showed
that the abortion rate at 24 h was significantly higher in the vaginal group.41 Another randomised
controlled trial comparing vaginal administration versus sublingual administration by the World
Health Organization (WHO) also showed a higher effectiveness in the vaginal route (85.9%) than
sublingual administration (79.8%) in terminating second trimester pregnancies, but this result was
mainly driven by nulliparous women at 24 h. Fever was more prevalent with vaginal adminis-
tration.42 The results of all these trials indicate that the most effective route for administration of
misoprostol for termination of second trimester pregnancy was vaginal. Sublingual administrationPlease cite this article in press as: Lee VCY, et al., Issues in second trimester induced abortion (medical/
surgical methods), Best Practice & Research Clinical Obstetrics and Gynaecology (2010), doi:10.1016/
j.bpobgyn.2010.02.008
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vaginal bleeding.
Mifepristone, an antiprogesterone, is the only anti-progestin approved for induction of abortion.
However, only 0.2% (2 out of 956) women aborted after mifepristone alone without gemeprost within
36 h in one review.43 The low efficacy of mifepristone being used alone was confirmed by another
descriptive study.44 Since it can sensitise the uterus to the action of PGs, it is used nowadays mainly in
combination with PGs in induction of second trimester abortion. The effectiveness as a combination
regimen with the two PGE1 analogues was well proven by various studies.
40,45–47T
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FThe use of cervical ripening agent
The use of misoprostol as a cervical priming agent for second trimester abortion, as a single dose of
50 mg of misoprostol given buccally for 30 min the evening prior to induction, was reported by one
descriptive study, which included 19 women only. It showed that the median time from first dose of
misoprostol expulsion was 9.4 h compared with the historical cohort of 14 h.48 The insertion of
a Laminaria tent 12 hbefore theadministrationof sulprostonehasbeen showntobeeffective in reducing
the induction-to-abortion interval.49 However, the Laminaria tent did not shorten the induction-
to-abortion interval when the abortion was induced with vaginal misoprostol.50 Mifepristone is
a highly effective ripening agent. It can shorten the abortionprocess induced byPGs if it is given 36–48 h
before the administration of PGs. Reducing the interval betweenmifepristone and PG to 24 h or less will
lead to a significant increase in induction-to-abortion interval.51–53 The dose of mifepristone can be
reduced from 600 to 200 mg without loss of its efficacy.54,55 Mifepristone 600 mg given 48 h before
vaginal gemeprostwas shown tobemore effective in shortening the induction abortion interval than the
Laminaria tent inserted12 hbefore the administration of vaginal gemeprost.56 Another randomised trial
comparing mifepristone with Laminaria tent before vaginal misoprostol showed that the induction-
to-abortion time was significantly shorter in the mifepristone arm (mean, 10 h vs. 16 h, P¼ 0.01). Pain
with cervical ripeningwasalso significantly less in themifepristonegroupthan in the Laminariagroup.57
Therefore, the available evidence shows thatmifepristone is thedrugof choice forpriming thecervix and
uterus in second trimester medical abortion. Unfortunately, it is still not available in many countries.U
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Whenmifepristone is available, the recommendedregimen is200 mgmifepristone followedby800 mg
of vaginalmisoprostol 36–48 h later. Subsequent doses of 400 mg of misoprostol can be given orally every
3 h up to a maximum of four more doses.58 Other PG analogues such as gemeprost can be used if miso-
prostol is not available. When mifepristone is not available, misoprostol can be used alone to induce
abortion but the induction-to-abortion interval may be longer. Many regimens using misoprostol alone
have been found to be effective. From the results of the various clinical trials, the regimen of 400 mg of
vaginal misoprostol every 3 h up to a maximum of five doses appears to be an effective regimenwithout
a very high incidence of side effects.33 As a recent pharmacokinetic study showed that the absorption of
vaginalmisoprostolmight be impaired in the presenceof significant vaginal bleeding,misoprostolmay be
given orally or sublingually if the patient developed heavy bleeding. If the woman fails to abort after the
completionof thefirst courseofmisoprostol, a secondcourseofmisoprostol canbegiven12 hafter the last
dose of themisoprostol. Since the uterus ismore sensitive to the action of PGswith increase in gestational
age, a lower dose of PG or less frequent administration should be consideredwith pregnancies beyond 22
weeks. Medical abortion in pregnancies beyond 22 weeks may lead to the delivery of a potentially viable
foetus. As recommended by the Royal College of Obstetricians and Gynaecologists (RCOG), intracardiac
potassium chloride, one of the most commonly used foeticidal agents, should be used to induce foetal
demise before medical abortion at 22 weeks gestation.58 Potassium chloride is injected trans-
abdominally under ultrasound guidance into the foetal cardiac ventricle or thorax. Digoxin, another
commonly used foeticide, can be given by various routes, including injection into the amniotic fluid or
other foetal tissues. Both agents were shown to be effective and safe.59,60Please cite this article in press as: Lee VCY, et al., Issues in second trimester induced abortion (medical/
surgical methods), Best Practice & Research Clinical Obstetrics and Gynaecology (2010), doi:10.1016/
j.bpobgyn.2010.02.008
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Complication and risks
The most common side effects of PG analogues in second trimester abortion were nausea (64.7%),
vomiting (22%) and chills (27.4%).61 Fever was another commonly reported side effect, especially with
misoprostol administration. The incidence was reported as 30–50% of womenwith 400 mg misoprostol
every 3 h.31 The probability of heavy bleeding requiring blood transfusion was 0.7%.44
A rare, but potentially life-threatening complication, is uterine rupture. Uterine rupture has been
reported to occur in women undergoing second trimester abortion induced by either misoprostol or
gemeprost.62,63
Pain relief
Abdominal cramping is common during second trimester medical abortion. Since some women
would perceive pain as a very important factor in choosing the method of abortion, pain relief during
abortion is of utmost importance. There are various reports regarding pain relief for abortion. A recent
double-blind randomised controlled trial compared 500 mg paracetamol with 400 mg ibuprofen for
pain relief with the regimen of 600 mg mifepristone orally followed by 400 mg of oral misoprostol 48 h
later for first-trimester abortion. The investigators found no significant difference in the complete
abortion rates, the mean pain score after misoprostol and no significant difference in the time of onset
of pain. However, there was a significant difference between the two groups in mean pain scores after
administration of the respective analgesics, with the ibuprofen group achieving greater reduction in
pain compared with the paracetamol group. In addition, the number of womenwho asked for second-
line analgesia (dipyrone) was significantly higher in the group that received paracetamol (26.5%) than
in the group receiving ibuprofen (6.2%).61 A retrospective analysis on the use of 3–4-hourly intra-
muscular diamorphine 10 mg in second trimester abortion between gestations of 12 and 20 weeks
with the regimen of mifepristone and misoprostol showed that 76.2% of women needed diamorphine
for pain relief, while 3.6% of women (14 out of 386) required more than two doses of 10 mg intra-
muscular diamorphine administration.64 The use of intramuscular pethidine injection and epidural
analgesia were also reported in second trimester abortion or medical induction for foetal demise in
second or third trimester in 24% and 28% of patients,respectively.65,66 Therefore, non-steroidal anti-
inflammatory drugs can be used for pain relief without affecting the efficacy of the PGs in medical
abortion. However, it is expected that some women will need narcotic analgesics for pain relief.
Post-abortion care
After abortion of the foetus, the placenta is usually delivered soon afterwards. If the placenta is still
not delivered after 1–2 h, an intravenous oxytocin infusion may be set up to facilitate the expulsion of
the placenta. After delivery of the placenta, it should be inspected carefully to assess whether it is
complete. If it is incomplete, evacuation of the uterus should be performed. After delivery of the
placenta, the patient should be observed for a few hours to monitor the amount of vaginal bleeding.
During this period, future contraception can be discussed with the patient and appropriate advice can
be given before the patient is discharged from the hospital.
Second trimester abortion in women with prior caesarean
With the increase in the incidence of caesarean for delivery for various reasons, there is an increased
demand on performing abortion in women with prior caesarean. The safety issue and the relationship
with uterine rupture are of great concern. Both medical and surgical methods for second trimester
abortion were shown to be effective and safe.
Both misoprostol and gemeprost were found to be safe in this aspect. A small observational study in
Egypt of over 50 womenwith one prior caesarean delivery undergoing abortion between gestations of
16 and 26 weeks showed the safety of the use of four doses of 200 mg of misoprostol applied vaginally
every 4 h daily, with a 12-h nightly rest frommisoprostol applications. The success rate of the regimen
was 90% with no uterine rupture noted.67 In a retrospective study using gemeprost 1 mg every 3 h forPlease cite this article in press as: Lee VCY, et al., Issues in second trimester induced abortion (medical/
surgical methods), Best Practice & Research Clinical Obstetrics and Gynaecology (2010), doi:10.1016/
j.bpobgyn.2010.02.008
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a maximum of five pessaries over 24 h, the overall success rate of abortion within 72 h was 98.4% in
womenwith one to three prior caesarean deliveries. There was one case out of 67 having heavy vaginal
bleeding requiring emergency surgical removal of placenta and blood transfusion. One patient at 20
weeks pregnancy with two lower-segment transverse caesarean sections required hysterotomy due to
uncontrolled vaginal bleeding and hysterectomy during the procedures due to unresponsive uterine
atony.68 A small case series of 15 women with one to two prior low transverse caesarean deliveries
having second trimester abortion between gestations of 16 and 28 weeks revealed no uterine rupture
without specifically describing the regimen. There was one uterine rupture among the two women
with previous classical caesarean deliveries. The authors also performed a systematic review, which
showed the incidence of uterine rupture was 0.4% in women with one prior low transverse caesarean
delivery.69 Another systematic review estimated that the risk of uterine rupture among women with
a prior caesarean delivery undergoing second trimester abortion using misoprostol is 0.28% (95%
confidence interval (CI) 0.08–1%) after pooling results of 16 studies, including 3556 patients with three
uterine ruptures noted.70 In the case series of 91 women, it was also shown to be safe to use Laminaria
with D&E in women with one or several prior caesarean deliveries for second trimester abortion of
gestations 17–24 weeks with no uterine rupture reported.71
How to choose the method
Both surgical and medical methods for second trimester abortion are safe and effective. However,
the choice of the method very often depends on the availability of the surgical expertise in performing
D&E as well as the preference of the physician in charge. The choice of the method greatly varies in
different localities. For instance, in US, D&E is used in over 96% of second trimester abortions,2 while in
North Europe, namely Finland and Sweden, and China, almost all second trimester abortions were
performed medically.72 In a retrospective cohort study in US, where D&E was used in over 96% of
patients, the overall complication rate was significantly lower in patients who underwent D&E than in
patients who underwent medical abortion (4% vs. 29%; P< 0.001). Medical abortions with misoprostol
resulted in a lower complication rate than abortions with other medications.10 There was one rand-
omised trial comparing D&E with the modern medical method of mifepristone followed by miso-
prostol. However, the study was stopped prematurely at 1 year because of slow enrolment with only 18
women participating. The regimen of mifepristone–misoprostol abortion caused more pain and
adverse events such as fever in three patients (33.3%). Three patients required surgical removal of the
placenta in the mifepristone–misoprostol group for retained placentae, while one patient required
suction curettage 6 days after abortion for retained products of conception.73 A recent Cochrane review
showed D&E was related to a lower combined incidence of minor complications than intra-amniotic
instillation of PGF2a (odds ratio (OR) 0.17, 95% CI 0.04–0.65), as was the total number of minor and
major complications (OR 0.12, 95% CI 0.03–0.46). The number of women experiencing adverse events
was also lowerwith D&E thanwithmifepristone andmisoprostol (OR 0.06, 95% CI 0.01–0.76). Although
women treated with mifepristone and misoprostol reported significantly more pain than those
undergoing D&E, efficacy and acceptability were the same in both groups.74 However, there was only
a single randomised trial comparing D&E with the mifepristone and misoprostol regimen and the
number of patients in this trial was small. Therefore, further randomised trials with a larger number of
patients are needed.
Specialised training and the maintenance of an adequate caseload are required to perform D&E
safely. Inexperienced providers are advised to use medical methods.58 From a survey of National
Abortion Federation members (NAF) in North America and Australia, 72% of NAF clinics offer second
trimester abortion services. The majority of second trimester providers are obstetricians/gynecologists
(63%), male (62%) and at least 50 years old (63%). What raised their concern was the ageing of skilled
practitioners, which may affect the future availability of second trimester abortion.75
If the surgical expertise of D&E is available, both surgical and medical methods should be offered to
the women who request second trimester termination of pregnancy and let them make their own
choice based on the information provided and their acceptance. However, if the surgical expertise for
D&E is not available, medical treatment should provide a safe option in case of second trimester
abortion.Please cite this article in press as: Lee VCY, et al., Issues in second trimester induced abortion (medical/
surgical methods), Best Practice & Research Clinical Obstetrics and Gynaecology (2010), doi:10.1016/
j.bpobgyn.2010.02.008
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Conclusion
D&E is the surgical method of choice for second trimester abortion but it requires gynaecologists,
who have been properly trained, appropriate instruments and adequate caseload to maintain the skill.
The combination of mifepristone and misoprostol is the regimen of choice for medical abortion in the
second trimester. Both D&E and the mifepristone/misoprostol medical abortion are safe and effective.
The choice will depend on the availability of the appropriate facilities and expertise. If possible, the
wish of the patients should also be taken into consideration.
Larger trials on the direct comparison of misoprostol with mifepristone versus D&E should be
carried out to elucidate the choice of method to provide second trimester abortion. Although the
combination of mifepristone and misoprostol is a safe and effective option, mifepristone is not widely
available. Other potentially useful agents should be explored to provide alternatives for mifepristone.C
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Practice points
 Proper preoperative assessment is a prerequisite for the provision of safe second trimester
abortion, no matter which method is used.
 D&E is the method of choice for surgical abortion in the second trimester. Adequate preop-
erative cervical dilatation with intracervical tents with or without misoprostol is essential to
reduce the risk of complications.
 To provide a safe D&E, adequate training of the gynaecologists is vital. It is also important to
have the appropriate instruments and an adequate caseload to maintain the surgical
expertise.
 The regimen of mifepristone followed by misoprostol is the method of choice for medical
abortion in the second trimester.
 Misoprostol alone may be used if mifepristone is not available, although it is associated with
longer induction-to-abortion interval and more side effects.
 Both surgical and medical methods, if available, should be discussed and offered to patients
requesting second trimester abortion.
 If surgical expertise for second trimester abortion is not available, medical abortion with
misoprostol with or without mifepristone should be offered.
Research agenda
 Larger randomised trials on the comparison of medical abortion with misoprostol together
with mifepristone and D&E.
 Trials on other agents potentially useful for medical abortion.U
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